https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-7-2026/ 2026-05-07T22:58:32Z Pharminent en Rare Disease & Gene Therapy Digest • May 7, 2026 2026-05-07T22:58:28Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-7-2026/ 2026-05-07T17:09:07Z Pharminent en Strategic News Watch • May 7, 2026 2026-05-07T17:09:03Z Blog https://pharminent.com/fda-reverses-course-on-atara-pierre-fabres-twice-rejected-cell-therapy-after-prasads-exit/ 2026-05-07T15:56:11Z Pharminent en FDA reverses course on Atara, Pierre Fabre's twice-rejected cell therapy after Prasad's exit 2026-05-07T14:57:05Z Blog https://pharminent.com/angelini-inks-4-1b-catalyst-buy-to-enter-us-rare-disease-market/ 2026-05-07T15:56:15Z Pharminent en Angelini inks $4.1B Catalyst buy to enter US rare disease market 2026-05-07T14:46:04Z Blog https://pharminent.com/bayer-plans-filings-for-cardiac-amyloidosis-imaging-agent/ 2026-05-07T15:56:18Z Pharminent en Bayer plans filings for cardiac amyloidosis imaging agent 2026-05-07T12:53:11Z Blog https://pharminent.com/roche-buys-ai-powered-diagnostics-player-pathai/ 2026-05-07T15:56:20Z Pharminent en Roche buys AI-powered diagnostics player PathAI 2026-05-07T11:40:36Z Blog https://pharminent.com/ucb-and-cancer-research-uk-form-expanded-alliance-to-advance-novel-cancer-therapies/ 2026-05-08T16:00:29Z Pharminent en UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies 2026-05-07T10:35:55Z Blog https://pharminent.com/eli-lilly-pledges-4-5bn-to-bolster-indiana-based-manufacturing/ 2026-05-08T15:59:36Z Pharminent en Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing 2026-05-07T10:30:55Z Blog https://pharminent.com/daiichi-sankyo-and-waiv-partner-for-adc-biomarkers-2/ 2026-05-07T16:27:26Z Pharminent en Daiichi Sankyo and Waiv partner for ADC biomarkers 2026-05-07T09:03:01Z Blog https://pharminent.com/halozyme-and-oruka-sign-agreement-for-hypercon-technology-2/ 2026-05-07T21:37:02Z Pharminent en Halozyme and Oruka sign agreement for Hypercon technology 2026-05-07T08:07:28Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-may-6-2026/ 2026-05-06T23:10:14Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • May 6, 2026 2026-05-06T23:10:10Z Blog https://pharminent.com/novo-nordisk-raises-guidance-on-strong-wegovy-pill-launch/ 2026-05-06T23:02:45Z Pharminent en Novo Nordisk Raises Guidance on Strong Wegovy Pill Launch 2026-05-06T22:58:40Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-may-6-2026/ 2026-05-06T19:08:56Z Pharminent en Manufacturing Intelligence • Weekly Digest • May 6, 2026 2026-05-06T19:08:53Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-6-2026/ 2026-05-06T17:31:22Z Pharminent en Strategic News Watch • May 6, 2026 2026-05-06T17:31:19Z Blog https://pharminent.com/fda-expands-ai-capabilities-and-completes-data-platform-consolidation/ 2026-05-07T15:56:20Z Pharminent en FDA Expands AI Capabilities and Completes Data Platform Consolidation 2026-05-06T16:57:45Z Blog https://pharminent.com/bayer-to-buy-perfuse-for-up-to-2-45b-bolstering-eye-drug-pipeline/ 2026-05-07T15:56:21Z Pharminent en Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline 2026-05-06T16:02:00Z Blog https://pharminent.com/novo-hikes-guidance-on-wegovy-pills-fast-sales-start/ 2026-05-06T16:39:36Z Pharminent en Novo hikes guidance on Wegovy pill's fast sales start 2026-05-06T15:26:21Z Blog https://pharminent.com/bayer-looks-to-uphold-eylea-legacy-with-2-45bn-perfuse-buyout/ 2026-05-06T16:39:39Z Pharminent en Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout 2026-05-06T15:13:21Z Blog https://pharminent.com/lilly-inflates-us-facility-investment-spending-by-4-5bn/ 2026-05-07T15:35:47Z Pharminent en Lilly inflates US facility investment spending by $4.5bn 2026-05-06T14:53:10Z Blog https://pharminent.com/fda-launches-one-day-inspectional-assessments-to-strengthen-and-expand-oversight/ 2026-05-06T16:39:41Z Pharminent en FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight 2026-05-06T14:00:46Z Blog https://pharminent.com/novos-wegovy-pill-reaches-1m-patients-shattering-expectations-with-355m-in-sales/ 2026-05-07T15:35:50Z Pharminent en Novo's Wegovy pill reaches 1M patients, shattering expectations with $355M in sales 2026-05-06T13:54:44Z Blog https://pharminent.com/cellcentric-secures-220m-in-europes-biggest-private-biotech-fundraise-of-2026/ 2026-05-06T16:45:25Z Pharminent en CellCentric secures $220M in Europe's biggest private biotech fundraise of 2026 2026-05-06T13:39:58Z Blog https://pharminent.com/gsk-bolts-on-sirna-drug-from-chinas-siranbio-in-1bn-deal/ 2026-05-06T16:39:43Z Pharminent en GSK bolts on siRNA drug from China's SiranBio in $1bn deal 2026-05-06T11:28:24Z Blog https://pharminent.com/cellcentric-raises-220m-for-a-transformative-multiple-myeloma-medicine/ 2026-05-06T16:39:43Z Pharminent en CellCentric raises $220M for a 'transformative' multiple myeloma medicine 2026-05-06T11:00:00Z Blog https://pharminent.com/msd-concludes-terns-acquisition-to-expand-cml-pipeline/ 2026-05-06T16:39:45Z Pharminent en MSD concludes Terns acquisition to expand CML pipeline 2026-05-06T10:15:16Z Blog https://pharminent.com/msd-concludes-terns-acquisition-to-expand-cml-pipeline-2/ 2026-05-06T16:09:19Z Pharminent en MSD concludes Terns acquisition to expand CML pipeline 2026-05-06T08:47:44Z Blog